17.90
0.17 (0.96%)
| 前收盘价格 | 17.73 |
| 收盘价格 | 17.88 |
| 成交量 | 526,737 |
| 平均成交量 (3个月) | 433,737 |
| 市值 | 907,036,544 |
| 市盈率 (P/E TTM) | 31.40 |
| 预期市盈率 (P/E Forward) | 13.44 |
| 价格/销量 (P/S) | 12.78 |
| 股市价格/股市净资产 (P/B) | 4.42 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 营业毛利率 | -89.38% |
| 营业利益率 (TTM) | -93.80% |
| 稀释每股收益 (EPS TTM) | -1.18 |
| 季度收入增长率 (YOY) | 6.10% |
| 总债务/股东权益 (D/E MRQ) | 29.01% |
| 流动比率 (MRQ) | 4.77 |
| 营业现金流 (OCF TTM) | 32.53 M |
| 杠杆自由现金流 (LFCF TTM) | 4.64 M |
| 资产报酬率 (ROA TTM) | -7.98% |
| 股东权益报酬率 (ROE TTM) | -31.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Theravance Biopharma, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | -4.0 |
| 价格波动 | -4.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.50 |
|
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 4.48% |
| 机构持股比例 | 91.75% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (BTIG, 123.46%) | 购买 |
| 中 | 28.00 (56.43%) | |
| 低 | 20.00 (HC Wainwright & Co., 11.73%) | 购买 |
| 平均值 | 29.33 (63.86%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 17.59 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 26 Nov 2025 | 40.00 (123.46%) | 购买 | 19.96 |
| HC Wainwright & Co. | 11 Nov 2025 | 20.00 (11.73%) | 购买 | 18.50 |
| B. Riley Securities | 12 Sep 2025 | 28.00 (56.42%) | 购买 | 14.30 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| FARNUM RHONDA | - | 17.90 | -9,060 | -162,174 |
| GRIMAUD BRETT A. | - | 17.90 | -19,024 | -340,530 |
| MILLER AINE | - | 17.90 | -6,989 | -125,103 |
| SAWAF AZIZ | - | 17.90 | -18,627 | -333,423 |
| WINNINGHAM RICK E | 17.73 | 17.82 | -56,817 | -1,017,024 |
| 累积净数量 | -110,517 | |||
| 累积净值 ($) | -1,978,254 | |||
| 累积平均购买 ($) | 17.73 | |||
| 累积平均卖出 ($) | 17.87 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| WINNINGHAM RICK E | 职员 | 20 Nov 2025 | 处理 (-) | 56,817 | 17.90 | 1,017,024 |
| FARNUM RHONDA | 职员 | 20 Nov 2025 | 处理 (-) | 9,060 | 17.90 | 162,174 |
| GRIMAUD BRETT A. | 职员 | 20 Nov 2025 | 处理 (-) | 19,024 | 17.90 | 340,530 |
| MILLER AINE | 职员 | 20 Nov 2025 | 处理 (-) | 6,989 | 17.90 | 125,103 |
| SAWAF AZIZ | 职员 | 20 Nov 2025 | 处理 (-) | 18,627 | 17.90 | 333,423 |
| WINNINGHAM RICK E | 职员 | 19 Nov 2025 | 处理 (-) | 9,900 | 17.73 | 175,527 |
| WINNINGHAM RICK E | 职员 | 19 Nov 2025 | 获得 (+) | 9,900 | 17.73 | 175,527 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合